Bharat Biotech is developing vaccines for the prevention and treatment of various bacterial and viral infections. A lead candidate from this programme, PvR II, is an antimalarial vaccine against Plasmodium vivax. PvR II targets the Duffy antigen binding protein, which enables P. vivax to bind to receptors on the red blood cells, providing the sole invasion pathway for this parasite. Preclinical development include vaccines for malaria and methicillin-resistant Staphylococcus aureus (MRSA) infections. Early research was underway for vaccines against human papillomavirus (HPV), non-typhoidal Salmonella infections, acellular pertussis, and a meat-free vaccine for tetanus. However, no recent reports of development have been identified for preclinical development in malaria and MRSA infections. Also, no recent reports of development have been identified for research development in HPV infections, pertussis, tetanus and Salmonella infections.
Vaccines for Chikungunya virus, Japanese encephalitis, Zika virus infection and typhoid have advanced into clinical development [see Adis Insight Drug profiles 800049688; 800035886; 800038671; 800053031; 800024027 respectively].
PvR II is being developed in collaboration with the International Centre for Genetic Engineering and Biotechnology (ICGEB), with funding provided by numerous national and international partners, including the Government of India's Department of Biotechnology, the WHO Tropical Disease Research Division, and the Indo-US Vaccine Action Programme, which is an alliance between the Department of Biotechnology, the US National Institutes of Health, and the PATH Malaria Vaccine Initiative. Additionally, development involves a technical collaboration with GlaxoSmithKline Biologicals.
Bharat is collaborating with the Center for Vaccine Development at The University of Maryland on the development of a conjugate vaccine for the prevention of non-typhoidal Salmonella infections  .
Key Development Milestones
In February 2016, Bharat Biotech announced that the preclinical in vivo studies are underway for ZikaVac®. The company is developing the vaccine as recombinant, using surface antigens of the Zika virus, and inactivated forms for Zika virus infections. The process development of the product was achieved at 40 litres pilot scale  .
In June 2012, Bharat Biotech and The University of Maryland Center for Vaccine Development received a $US4 million Strategic Translation Award from The Wellcome Trust for the clinical development of Bharat's conjugate vaccine for invasive non-typhoidal Salmonella infections. Bharat plans to begin clinical trials of the vaccine in 2015  .
Bharat Biotech files a global patent for Zika vaccine candidates  .